Free tool
FAERS Monitor: Survanta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020032 or its brand name (Survanta, Beractant). Reports on generic versions are filed under their own applications.
Reports
369
Serious
362
98% of reports
Hospitalization
72
Death reported
222
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pulmonary haemorrhage126
- death54
- neurodevelopmental disorder36
- pneumothorax34
- drug ineffective33
- sepsis19
- neonatal respiratory distress syndrome17
- endotracheal intubation complication16
- neonatal disorder16
- oxygen saturation decreased16
- respiratory failure15
- acute respiratory distress syndrome14
- bradycardia13
- cardiac arrest11
- general physical health deterioration7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 18 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 18 |
| 2012 | 15 |
| 2013 | 33 |
| 2014 | 70 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 33 |
| 2018 | 27 |
| 2019 | 16 |
| 2020 | 16 |
| 2021 | 8 |
| 2022 | 12 |
| 2024 | 8 |
| 2025 | 10 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neurodevelopmental disorderSignal | 36 | 3209.4 | 2330.9 | 106,305 |
| endotracheal intubation complicationSignal | 16 | 1590.4 | 978.1 | 23,204 |
| pulmonary haemorrhageSignal | 126 | 932.9 | 808.3 | 114,537 |
| neonatal disorderSignal | 16 | 581.8 | 359.4 | 8,618 |
| neonatal respiratory distress syndromeSignal | 17 | 275.2 | 172.8 | 4,353 |
| pneumothoraxSignal | 34 | 122.5 | 88.9 | 3,971 |
| acute respiratory distress syndromeSignal | 14 | 45.2 | 27.0 | 561 |
| oxygen saturation decreasedSignal | 16 | 16.2 | 10.1 | 214 |
| bradycardiaSignal | 13 | 14.0 | 8.2 | 144 |
| respiratory failureSignal | 15 | 11.7 | 7.1 | 137 |
| sepsisSignal | 19 | 9.7 | 6.3 | 141 |
| cardiac arrestSignal | 11 | 7.6 | 4.2 | 57 |
| deathSignal | 54 | 3.6 | 2.8 | 102 |
| general physical health deteriorationSignal | 7 | 3.4 | 1.7 | 10 |
| drug ineffective | 33 | 1.4 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.